Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2 - Archive ouverte HAL
Article Dans Une Revue Emerging microbes & infections Année : 2021

Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2

Kahina Saker
Mary-Anne Trabaud
Guillaume Thiery
Thomas Bourlet
Florence Morfin
Sophie Trouillet-Assant
Bruno Pozzetto

Résumé

SARS-CoV-2 mutations appeared recently and can lead to conformational changes in the spike protein and probably induce modifications in antigenicity. We assessed the neutralizing capacity of antibodies to prevent cell infection, using a live virus neutralization test with different strains [19A (initial one), 20B (B.1.1.241 lineage), 20I/501Y.V1 (B.1.1.7 lineage), and 20H/501Y.V2 (B.1.351 lineage)] in serum samples collected from different populations: two-dose vaccinated COVID-19-naive healthcare workers (HCWs; Pfizer-BioNTech BNT161b2), 6-months post mild COVID-19 HCWs, and critical COVID-19 patients. No significant difference was observed between the 20B and 19A isolates for HCWs with mild COVID-19 and critical patients. However, a significant decrease in neutralization ability was found for 20I/501Y.V1 in comparison with 19A isolate for critical patients and HCWs 6-months post infection. Concerning 20H/ 501Y.V2, all populations had a significant reduction in neutralizing antibody titers in comparison with the 19A isolate. Interestingly, a significant difference in neutralization capacity was observed for vaccinated HCWs between the two variants but not in the convalescent groups.

Fichier principal
Vignette du fichier
TEMI_10_1945423.pdf (2.08 Mo) Télécharger le fichier
Origine Accord explicite pour ce dépôt
Licence

Dates et versions

hal-04872689 , version 1 (08-01-2025)

Licence

Identifiants

Citer

Carla Saade, Claudia Gonzalez, Antonin Bal, Martine Valette, Kahina Saker, et al.. Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2. Emerging microbes & infections, 2021, 10, pp.1499 - 1502. ⟨10.1080/22221751.2021.1945423⟩. ⟨hal-04872689⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More